Cerluten

Cerluten (also written Церлутен) is a proprietary low-molecular-weight peptide complex (typically up to 5,000–10,000 Da) extracted from the cerebral cortex tissue of young calves (under 12 months of age). It belongs to the Cytomax line of tissue-specific peptide bioregulators developed under the research of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.

Unlike synthetic single-sequence peptides such as Cortagen (AEDP), Cerluten remains a multi-peptide extract. It is sold primarily as oral capsules (commonly 10 mg active peptide complex per capsule) and, in some markets, as a sublingual (lingual) liquid form. It is classified as a biologically active food supplement (dietary supplement), not a registered pharmaceutical drug in most Western jurisdictions, and is not FDA- or EMA-approved.

Primary active component: Peptide complex A-5 (brain/CNS peptides). Typical capsule size: 0.2 g total weight.

How Cerluten Is Proposed to Work

According to the bioregulator peptide framework:

• Short peptides from brain tissue are thought to act in a tissue-specific manner.
• They may help normalize metabolic processes and protein synthesis in neural cells.
• Proposed mechanisms include modulation of gene expression in neural tissue, antioxidant effects on lipid peroxidation in the cortex, and support for cellular adaptation under stress or age-related decline.

The peptides are claimed to support the functional activity of neurons rather than act as classical nootropics or stimulants. Absorption occurs via the digestive tract (capsules) or more rapidly via sublingual mucosa (lingual form).

Potential Benefits and Common Uses

Marketing and Russian-language research materials associate Cerluten with support in the following areas (evidence levels vary and are mostly open-label or developer-affiliated):

• Cognitive function, memory, and attention
• Mental clarity and reduced “brain fog”
• Recovery support after stroke, traumatic brain injury, or vascular encephalopathy
• Age-related changes in the central nervous system
• Emotional balance, sleep quality, and reduced subjective fatigue
• Adaptation under high mental load or extreme conditions

A frequently cited 2003–2004 open clinical observation at the St. Petersburg Institute involved 48 patients with residual effects of TBI, post-stroke states, vascular encephalopathies, or reduced mental capacity. Reported outcomes included clinical improvement in approximately 65% of the Cerluten group, with reductions in complaints related to memory, headaches, emotional state, and sleep. No serious adverse effects were noted in that cohort.

Independent, large-scale, placebo-controlled Western trials are limited. Stronger neuroprotective data exist for the related injectable preparation Cortexin and the synthetic peptide Cortagen.

Dosage and Administration

Standard oral capsule protocol (based on product labeling and common recommendations):

• Adults: 1–2 capsules (10–20 mg peptide complex), 1–2 times daily with meals
• Course length: 10–30 days (commonly 20–30 days)
• Frequency: 2–3 courses per year, or as advised
• Daily peptide intake in typical regimens: 20 mg (2 capsules)

Sublingual (lingual) form (where available):

• Often 5–6 drops under the tongue, 10–15 minutes before meals, several times daily
• Course: approximately 1 month

Safety, Contraindications, and Side Effects

Reported profile: Generally well-tolerated in available Russian studies, with no serious adverse events noted in the small clinical observation. No evidence of dependence.

Contraindications (per product information):

• Individual hypersensitivity to components
• Pregnancy
• Breastfeeding / lactation

Storage: Dry, dark place at 2–25 °C. Shelf life typically 5 years.

Cerluten is derived from animal tissue. Quality, purity, and batch consistency can vary by manufacturer. It is not a substitute for medical treatment of neurological disease.

Cerluten vs Related Peptides

Who Might Consider Cerluten?

Individuals interested in peptide bioregulators for cognitive maintenance, post-injury recovery support, or age-related brain health often explore Cerluten. It appeals to those seeking an oral option rather than injectables. Results are individual, and it should not replace evidence-based medical care.

Frequently Asked Questions

Is Cerluten FDA-approved? No. It is sold as a dietary supplement in certain markets.

Can it be stacked with other peptides? Some users combine it with other Khavinson bioregulators (e.g., pineal or vascular peptides), but medical supervision is recommended.

How long until effects appear? Subjective improvements in energy, focus, or sleep are sometimes reported within or after a course; objective data come mainly from the short clinical observation described above.

Is it the same as Cerebrolysin or Cortexin? No. Cerebrolysin is a different porcine brain hydrolysate (injectable). Cortexin is a related but distinct registered preparation.